RPE65 and glycogen storage disease VI: The Rpe65-KO mouse (Redmond et al., 1998) and a naturally occurring Briard dog model of RPE65 disease were instrumental in developing this treatment, providing the opportunity to examine and prove safety and efficacy of the vectors prior to application in human patients (Acland et al., 2001; Pang et al., 2006).